Belcic Mikic T, Sterle I, Maticic M, Arnol M
Biomedicines. 2025; 13(2).
PMID: 40002884
PMC: 11853736.
DOI: 10.3390/biomedicines13020472.
Leeies M, Doucette K, Dufault B, Carta T, Mooney O, Hrymak C
Clin Transplant. 2024; 38(12):e70058.
PMID: 39708307
PMC: 11662980.
DOI: 10.1111/ctr.70058.
Dilwali N, Hartley C, Sue P, Karnsakul W
Pathogens. 2024; 13(11).
PMID: 39599500
PMC: 11597609.
DOI: 10.3390/pathogens13110947.
Papanikolla J, McGowan M, Chunduru M, Winters H, Pesavento T, Smith R
Transpl Infect Dis. 2024; 26(6):e14366.
PMID: 39226149
PMC: 11666865.
DOI: 10.1111/tid.14366.
Chang J, Kudose S, Droubi S, Verduzco H, Awori J, Ratner L
Kidney Int Rep. 2024; 9(6):1903-1907.
PMID: 38899181
PMC: 11184312.
DOI: 10.1016/j.ekir.2024.04.010.
Patient Perspectives on Solid Organ Transplantation From Donors With Hepatitis C Viremia to Recipients Without Hepatitis C Viremia.
Vanterpool K, Diallo K, Kim E, Van Pilsum Rasmussen S, Johnson M, Predmore Z
Open Forum Infect Dis. 2024; 11(3):ofae015.
PMID: 38434612
PMC: 10906703.
DOI: 10.1093/ofid/ofae015.
Twelve-month kidney and liver outcomes of kidney transplantation from Hepatitis C Viremic deceased donors to aviremic recipients.
Binari L, Thorne P, Rega S, Feurer I, Shawar S, Naik R
Transpl Infect Dis. 2023; 26(1):e14213.
PMID: 38112078
PMC: 10922352.
DOI: 10.1111/tid.14213.
The Role of Gastroenterologists in Preoperative Assessment and Management of Prospective Renal Transplantation Candidates.
Giri S, Dash K, Varghese J, Afzalpurkar S
Euroasian J Hepatogastroenterol. 2023; 13(1):18-25.
PMID: 37554975
PMC: 10405807.
DOI: 10.5005/jp-journals-10018-1390.
Shifting perspectives in liver diseases after kidney transplantation.
Kosuta I, Ostojic A, Vujaklija Brajkovic A, Babel J, Simunov B, Sremac M
World J Hepatol. 2023; 15(7):883-896.
PMID: 37547033
PMC: 10401415.
DOI: 10.4254/wjh.v15.i7.883.
Longer-Term Clinical Outcomes From the THINKER and EXPANDER Trials of Transplantation of HCV-RNA+ Donor Kidneys Into Hepatitis C Virus-Negative Recipients.
Potluri V, Naqvi F, Goldberg D, Shah M, Loupy A, Abt P
Kidney Int Rep. 2023; 8(7):1460-1463.
PMID: 37441470
PMC: 10334397.
DOI: 10.1016/j.ekir.2023.04.018.
Effectiveness of education and attitudes toward different types of deceased donor kidneys: Survey analysis of single-center experience.
Nair S, Thorp A, Hanna W, Johnson B, Smith B, Iyengar S
Front Public Health. 2023; 11:1116823.
PMID: 37064665
PMC: 10090271.
DOI: 10.3389/fpubh.2023.1116823.
Observational Study Examining Kidney Transplantation Outcomes Following Donation From Individuals That Died of Drug Toxicity in British Columbia, Canada.
Xie M, Kennan S, Slaunwhite A, Rose C
Can J Kidney Health Dis. 2023; 10:20543581231156853.
PMID: 37051047
PMC: 10084533.
DOI: 10.1177/20543581231156853.
The association of center volume with transplant outcomes in selected high-risk groups in kidney transplantation.
Merzkani M, Chang S, Murad H, Lentine K, Mattu M, Wang M
BMC Nephrol. 2023; 24(1):61.
PMID: 36941609
PMC: 10029277.
DOI: 10.1186/s12882-023-03099-0.
Analysis of the effects of donor and recipient hepatitis C infection on kidney transplant outcomes in the United States.
Yuan Q, Hong S, Leya G, Roth E, Tsoulfas G, Williams W
World J Transplant. 2023; 13(2):44-57.
PMID: 36908306
PMC: 9993188.
DOI: 10.5500/wjt.v13.i2.44.
Acute hepatitis C virus infection: clinical update and remaining challenges.
Liu C, Kao J
Clin Mol Hepatol. 2023; 29(3):623-642.
PMID: 36800699
PMC: 10366792.
DOI: 10.3350/cmh.2022.0349.
Trends in use and three-year outcomes of hepatitis C virus-viremic donor lung transplants for hepatitis C virus-seronegative recipients.
Ruck J, Zeiser L, Zhou A, Chidi A, Winchester S, Durand C
J Thorac Cardiovasc Surg. 2022; 165(4):1587-1595.e2.
PMID: 36207160
PMC: 9989038.
DOI: 10.1016/j.jtcvs.2022.08.019.
Factors Underlying Racial Disparity in Utilization of Hepatitis C-Viremic Kidneys in the United States.
Atiemo K, Baudier R, Craig-Schapiro R, Guo K, Mazumder N, Anderson A
J Racial Ethn Health Disparities. 2022; 10(5):2185-2194.
PMID: 35997960
PMC: 10348076.
DOI: 10.1007/s40615-022-01398-0.
Utilization of HCV Viremic Kidneys with Genotyping/Subtyping-Free Sofosbuvir/Velpatasvir Treatment Strategy: Experience from China.
Zhang H, Liu Q, Hu S, Zhong M, Peng F, Guo Y
Biomed Res Int. 2022; 2022:3758744.
PMID: 35941983
PMC: 9356870.
DOI: 10.1155/2022/3758744.
Decision-making Among Hepatitis C Virus-negative Transplant Candidates Offered Organs from Donors with HCV Infection.
Saine M, Schnellinger E, Liu M, Diamond J, Crespo M, Prenner S
Transplant Direct. 2022; 8(8):e1341.
PMID: 35923812
PMC: 9298473.
DOI: 10.1097/TXD.0000000000001341.
Pan-genotypic direct-acting antivirals for patients with hepatitis C virus infection and chronic kidney disease stage 4 or 5.
Liu C, Kao J
Hepatol Int. 2022; 16(5):1001-1019.
PMID: 35876967
PMC: 9309604.
DOI: 10.1007/s12072-022-10390-z.
